biostudies-literatureUnknown12Miyao KFifth District Eagles Cancer TelethonGerstner Family FoundationNational Institutes of HealthHenry J. Predolin Foundation for Research in LeukemiaPrimary central nervous system lymphoma (PCNSL) is a rare form and aggressive type of diffuse large B-cell lymphoma (DLBCL) that occurs in both immunocompetent and immunocompromised adults. While adding rituximab to chemotherapeutic regimens resulted in dramatic improvement in both progression-free survival and overall survival in patients with non-central nervous system (CNS) DLBCL, the outcomes of PCNSL are generally poor due to the immune-privileged tumor microenvironment or suboptimal delivery of systemic agents into tumor tissues. Therefore, more effective therapy for PCNSL generally requires systemic therapy with sufficient CNS penetration, including high-dose intravenous methotrexate with rituximab or high-dose chemotherapy followed by autologous stem cell transplantation. However, Frontiers in oncology1082235https://www.ebi.ac.uk/biostudies/studies/S-EPMC9850100biostudies-literatureIs CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?PMC9850100Miyao KSakemura RLYokota HfalseIs CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?Primary central nervous system lymphoma (PCNSL) is a rare form and aggressive type of diffuse large B-cell lymphoma (DLBCL) that occurs in both immunocompetent and immunocompromised adults. While adding rituximab to chemotherapeutic regimens resulted in dramatic improvement in both progression-free survival and overall survival in patients with non-central nervous system (CNS) DLBCL, the outcomes of PCNSL are generally poor due to the immune-privileged tumor microenvironment or suboptimal delivery of systemic agents into tumor tissues. Therefore, more effective therapy for PCNSL generally requires systemic therapy with sufficient CNS penetration, including high-dose intravenous methotrexate with rituximab or high-dose chemotherapy followed by autologous stem cell transplantation. However, 2022-01-01T00:00:00Z20222025-04-04T08:33:49.946Z2025-04-04T08:33:49.946ZS-EPMC98501003668682110.3389/fonc.2022.1082235